Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mesothelioma
Biotech
Vivace hits high note in midstage mesothelioma trial
Vivace plans to launch a phase 3 study of potential first-in-class VT3989 in mesothelioma in the first half of 2026.
Darren Incorvaia
Oct 19, 2025 10:30am
Ultimovacs links BMS-cancer vaccine combo to improved survival
Oct 18, 2023 8:40am
Atara reviewing patient death in mesothelioma CAR-T study
Feb 18, 2022 1:05pm
Biopharma charts progress in translating CAR-T to solid cancers
Dec 15, 2021 3:00am
Sanofi inks $270M cancer AI deal with developer Owkin
Nov 18, 2021 1:30am
SITC: Cellectis off-the-shelf CAR-T active in solid tumor models
Nov 12, 2021 10:50am
